OXB.L vs RGEN
OXB.L: A leader in the viral vector manufacturing sector, providing essential development and production services for advanced cell and gene therapy treatments. RGEN: Repligen provides critical bioprocessing technologies and consumables that enable the efficient manufacturing of biological medicines and advanced therapies.
Side-by-side fundamentals
| Metric | OXB.L | RGEN | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £5.61 | $158.59 | |
| Market cap as of 2026-08-06 | n/a | $9.0B | |
| P/E as of 2026-08-06 | n/a | 211.44 | |
| PEG as of 2026-08-06 | n/a | 8.65 | |
| Net margin as of 2026-08-06 | n/a | +5.3% | |
| Gross margin as of 2026-08-06 | n/a | +53.8% | |
| Operating margin as of 2026-08-06 | n/a | +6.5% | |
| ROE as of 2026-08-06 | n/a | +2.0% | |
| ROA as of 2026-08-06 | n/a | +1.4% | |
| Debt / equity as of 2026-08-06 | n/a | 0.26 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +16.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +30.5% | |
| Beta as of 2026-08-06 | n/a | 1.09 | |
| 1-year return as of 2026-08-03 close | +20.8% | +36.9% | RGEN higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.